Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells

Patent metadata

Field	Value
Publication number	US-9499634-B2
Application number	US-201313927065-A
Country	US
Kind code	B2
Filing date	Jun 25, 2013
Priority date	Jun 25, 2012
Publication date	Nov 22, 2016
Grant date	Nov 22, 2016

Abstract

The present invention provides a process and methods for producing asymmetric antibodies in a mammalian expression system. The asymmetric antibodies are transiently or stably expressed and in cells that stably express the asymmetric antibody, following a rapid 2-step process of stable pool to clone, a highly pure asymmetric antibody expressing clone can be identified at a success frequency that permits for screening of tens of clones rather than thousands. The asymmetric antibodies are produced at a high titre and with a high level of purity with no contaminating homodimer antibodies following protein A purification with a step yield of near 100%. Typical downstream purification processes employ standard hydrophobic interaction chromatography (HIC) and/or cation exchange (CEX) resins and the antibody is stable within a wide dynamic range of buffer pH (4-8) and within the requirements for manufacturing antibodies for pre-clinical and clinical applications.

First claim

We claim:

1. A method of producing an asymmetric antibody product comprising a first heavy chain polypeptide, a second heavy chain polypeptide, and at least one light chain polypeptide in stable mammalian cells, the method comprising:
A. selecting a first heavy chain polypeptide sequence and a second heavy chain polypeptide sequence, each of the first and second heavy chain polypeptide sequences comprising a variant CH3 sequence, wherein the variant CH3 sequence of the first heavy chain polypeptide sequence is different from the variant CH3 sequence of the second heavy chain polypeptide sequence,
wherein the variant CH3 sequence of the first heavy chain polypeptide comprises amino acid modifications at positions F405 and Y407, optionally in combination with an amino acid modification at position L351, and the variant CH3 sequence of the second heavy chain polypeptide comprises amino acid modifications at positions T366 and T394, optionally in combination with a modification at position K392,
wherein the amino acid modification at position T366 is T366I, T366L, T366M or T366V; the amino acid modification at position T394 is T394W; the amino acid modification at position F405 is F405A, F405T, F405S or F405V; the amino acid modification at position Y407 is Y407V; the amino acid modification at position L351 is L351Y; and the amino acid modification at position K392 is K392L, K392M, K392V or K392F, and
wherein the variant CH3 sequences of the first and second heavy chain polypeptides promote formation of a heterodimeric Fc region with a CH3 domain having a Tm greater than 75° C.;
B. (i) transfecting at least two different mammalian cells with different ratios of a first DNA sequence encoding the first heavy chain polypeptide sequence, a second DNA sequence encoding the second heavy chain polypeptide sequence and at least one DNA sequence encoding a light chain polypeptide such that each of the at least two mammalian cells expresses the heavy chain polypeptides and the at least one light chain polypeptide in a different ratio, and
(ii) selecting, as a pre-determined ratio, a ratio of the first DNA sequence, the second DNA sequence and the at least one DNA sequence encoding a light chain polypeptide that results in a mammalian cell line that produces greater than 75% asymmetric antibody product, less than 10% monomers, and undetectable amounts of homodimers of said first or second heavy chain polypeptide;
C. transfecting at least one mammalian cell with the pre-determined ratio of the first DNA sequence, the second DNA sequence, and the at least one DNA sequence encoding a light chain polypeptide to generate stable mammalian cells;
D. culturing said stable mammalian cells under conditions suitable for expression of the first and second heavy chain polypeptides and the light chain polypeptide to produce the asymmetric antibody product, whereby stable mammalian cells producing greater than 75% asymmetric antibody product, less than 10% monomers, and undetectable amounts of homodimers of said first or second heavy chain polypeptide are obtained at a frequency of greater than 1 in 500.

2. The method of claim 1 , wherein the at least one mammalian cell is transfected with a multi-cistronic vector comprising said first DNA sequence, said second DNA sequence and said at least one DNA sequence encoding a light chain.

3. The method of claim 1 , wherein the first DNA sequence, the second DNA sequence and the at least one DNA sequence encoding a light chain are each on separate expression vectors.

4. The method of claim 1 , wherein said pre-determined ratio of the first DNA sequence:second DNA sequence:DNA sequence encoding light chain polypeptide is between about 1:1:2 and about 1:1:3.

5. The method of claim 1 , wherein said pre-determined ratio of the first DNA sequence:second DNA sequence:at least one DNA sequence encoding light chain polypeptide is such that the amount of translated first heavy chain polypeptide is about equal to the amount of the second heavy chain polypeptide, and the amount of the at least one light chain polypeptide is at least about two fold greater than the amounts of either of the heavy chain polypeptides.

6. The method of claim 1 wherein the asymmetric antibody product further comprises a CH2 domain with wild-type stability.

7. The method of claim 1 , wherein the heterodimeric Fc region has a CH3 domain with a Tm greater than 80° C.

8. The method of claim 1 , wherein
a. the variant CH3 sequence of the first heavy chain polypeptide comprises the amino acid modifications L351Y, F405A, and Y407V, and the variant CH3 sequence of the second heavy chain polypeptide comprises the amino acid modifications T366L, K392M, and T394W;
b. the variant CH3 sequence of the first heavy chain polypeptide comprises the amino acid modifications L351Y, F405A, and Y407V, and the variant CH3 sequence of the second heavy chain polypeptide comprises the amino acid modifications T366L, K392L, and T394W;
c. the variant CH3 sequence of the first heavy chain polypeptide comprises the amino acid modifications T350V, L351Y, F405A, and Y407V, and the variant CH3 sequence of the second heavy chain polypeptide comprises the amino acid modifications T350V, T366L, K392M, and T394W; or
d. the variant CH3 sequence of the first heavy chain polypeptide comprises the amino acid modifications T350V, L351Y, F405A, and Y407V, and the variant CH3 sequence of the second heavy chain polypeptide comprises the amino acid modifications T350V, T366L, K392L, and T394W.

9. The method of claim 1 , wherein the stable mammalian cells produce the asymmetric antibody product with a titer of greater than 100 mg/L.

10. The method of claim 1 , wherein said at least one mammalian cell is selected from the group consisting of a VERO, HeLa, HEK, NS0, Chinese Hamster Ovary (CHO), W138, BHK, COS-7, Caco-2 and MDCK cell, and subclasses and variants thereof.

11. The method of claim 1 , wherein the at least one mammalian cell is one that produces a glycosylated asymmetric antibody product.

12. The method of claim 1 , wherein the at least one mammalian cell is a pool of mammalian cells.

13. The method of claim 1 , further comprising the step of selecting a stable monoclonal mammalian cell that produces greater than 75% asymmetric antibody product, less than 10% monomers, and undetectable amounts of homodimers of said first or second heavy chain polypeptide from the stable mammalian cells generated in step D.

14. The method of claim 1 , wherein the frequency of obtaining stable mammalian cells producing greater than 75% asymmetric antibody product, less than 10% monomers, and undetectable amounts of homodimers of said first or second heavy chain polypeptide is greater than 1 in 200.

15. The method of claim 1 , wherein the amount of asymmetric antibody product, monomer and homodimer is determined by at least one of SDS-PAGE, liquid chromatography, mass spectrometry and combinations thereof.

16. The method of claim 1 , further comprising one or more purification steps to obtain a purified asymmetric antibody product, the one or more purification steps selected from protein A column chromatography, cation exchange chromatography, anion membrane capture, and hydrophobic interaction chromatography.

17. The method of claim 1 , wherein the ratio of said first DNA sequence:second DNA sequence in the transfected cell is such that the amount of translated first heavy chain polypeptide is about equal to the amount of translated second heavy chain polypeptide.

18. The method of claim 1 , wherein the stable mammalian cells produc

Assignees

• Zymeworks Inc

Inventors

• Dixit Surjit Bhimarao
• Ng Gordon Yiu Kon
• Spreter Von Kreudenstein Thomas

Classifications

• C07K2317/41

  Glycosylation, sialylation, or fucosylation · CPC title

• C07K2317/14

  Specific host cells or culture conditions, e.g. components, pH or temperature · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title

• C07K2317/526

  CH3 domain · CPC title

• C07K16/46 Primary

  Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00) · CPC title